Quantcast

Latest cell therapy Stories

2014-07-01 11:10:06

American Association for Cancer Research A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. This new approach may help develop more effective cancer immunotherapies, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. "This study...

2014-07-01 11:00:54

HSC Mesenchymal stem cells have become attractive tools for bioengineers, but some scientists haven’t given up on their regenerative potential Stem cell scientists had what first appeared to be an easy win for regenerative medicine when they discovered mesenchymal stem cells several decades ago. These cells, found in the bone marrow, can give rise to bone, fat, and muscle tissue, and have been used in hundreds of clinical trials for tissue repair. Unfortunately, the results of these...

2014-06-30 08:31:42

GERMANTOWN, Md., June 30, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) reports that its shares have been added to the broad-market Russell 3000(®) Index. Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000(®) Index or small-cap Russell 2000(®) Index...

2014-06-30 08:31:13

PORTLAND, Oregon, June 30, 2014 /PRNewswire/ -- According to a new market research report by Allied Market Research titled, "GlobalRegenerative MedicineMarket (Technology, Applications, Geography) - Industry Analysis, Trends, Opportunities and Forecast, 2013-2020", the global regenerative medicine market will reach $ 67.6 billion by 2020 from $16.4 billion in 2013, registering a CAGR of 23.2% during forecast period (2014 - 2020). Small molecules and biologics segment holds...

2014-06-27 23:05:47

A new study released today in STEM CELLS Translational Medicine suggests a new way to produce endothelial progenitor cells in quantities large enough to be feasible for use in developing new cancer treatments. Durham, NC (PRWEB) June 27, 2014 A new study released today in STEM CELLS Translational Medicine suggests a new way to produce endothelial progenitor cells in quantities large enough to be feasible for use in developing new cancer treatments. Endothelial progenitor cells (EPCs) are...

2014-06-25 12:30:18

HLI Co-Founder, Robert Hariri Speaks on Medical Innovation at 2014 BIO International Convention in San Diego LA JOLLA, Calif., June 25, 2014 /PRNewswire/ -- Human Longevity, Inc. (HLI), a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, today called on physicians, the insurance industry and political leaders to support promising new avenues of medical discovery on behalf of patients with...

2014-06-25 08:30:00

Positions Company to Participate in One of the Fastest Growing Areas of Stem Cell Research LAS VEGAS, June 25, 2014 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company"), announced today the launch of a new service offering for the isolation and expansion of mesenchymal stem cells through its wholly owned subsidiary CorCell Companies, Inc. (CorCell). This service was researched and developed in CorCell's laboratory...

2014-06-25 04:20:56

GOSSELIES, Belgium, June 25, 2014 /PRNewswire/ -- Minimally invasive bone forming product ALLOB(R)in Phase I/IIa trial for delayed union fracture Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the field of bone diseases and orthopaedics, today announces that the first patient has been treated with its novel allogeneic osteoblastic (bone-forming) cell therapy product ALLOB(R) in its phase...

2014-06-24 23:07:47

Today, in his keynote address at the Cell Science-2014 4th World Congress on Cell Science and Stem Cell Research in Valencia, Spain, Dr. James L. Sherley, Director of ASCTC, LLC, announced the June 24 issue of the company's newly approved patent for a method to produce iPSCs with a single non-genetic agent. The new technology – based on an underlying biological connection between adult tissue stem cells and iPSCs – has potential to provide a convenient and general method for...

2014-06-24 23:03:05

New research report “Cancer Cell Therapy Market & Pipeline Insight” elaborated by Kuick Research is now available at MarketPublishers.com London, UK (PRWEB) June 24, 2014 Over the past 5 years, the world cancer cell therapy market witnessed strong growth. Furthermore, this market is expected to keep on following an upward trend in the years ahead, driven by the increasing cancer incidence worldwide, rising adoption of novel drugs, high unmet needs along with the continuously...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.